Rapid Dosage Titration of Levetiracetam in Children

Vaisleib, Inna; Neft, Robyn A

doi:10.1592/phco.28.3.393

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Strikingly, dizziness and irritability have a similar frequency at all drug doses. M a n u s c r i p t Even though the reasons for these atypical findings are not clear, the lack of a dose-effect relationship for several AEs can explain the clinical profile of LEV, which is considered a drug with a very good tolerability [1,3] and which can be titrated very fast without severe consequences [40].…”

Section: A N U S C R I P Tmentioning

confidence: 99%

The adverse event profile of levetiracetam: A meta-analysis on children and adults

Verrotti

Prezioso

Sabatino

et al. 2015

Seizure

View full text Add to dashboard Cite

show abstract

Section: A N U S C R I P Tmentioning

confidence: 99%

The adverse event profile of levetiracetam: A meta-analysis on children and adults

Verrotti

Prezioso

Sabatino

et al. 2015

Seizure

View full text Add to dashboard Cite

show abstract

“…One prospective study of levetiracetam (n = 31) found higher rates of adverse effects in patients taking .45 mg/kg/day,3 whereas two other retrospective chart reviews (n = 3219 and n = 155) did not find that tolerability of levetiracetam is dose-dependent. Rapid titration of levetiracetam (1–14 days) can be well tolerated, although adverse effects were observed in 12%–22% of subjects 10,75…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age

Cormier¹,

Chu²

2013

NDT

View full text Add to dashboard Cite

Epilepsy is a common neurological disorder in the pediatric population, affecting up to one percent of children, and for which the mainstay of treatment is anticonvulsant medication. Despite the frequent use of anticonvulsant drugs, remarkably little is known about the safety and efficacy of most of these medications in the pediatric epilepsy population. Of 34 anticonvulsants currently approved for use by the US Food and Drug Administration (FDA), only 13 have been approved for use in children. Although infants and young children are disproportionately affected by epilepsy, there are currently only three anticonvulsant medications that have been specifically evaluated and approved for use in children younger than 2 years of age. In 2012, the FDA approved levetiracetam as an adjunctive treatment for partial onset seizures in infants and children from one month of age. Here we review the available data on levetiracetam in the pediatric epilepsy population. We first discuss the pharmacological profile of levetiracetam, including its mechanism of action, formulations and dosing, and pharmacokinetics in children. We then review the available efficacy, safety, and tolerability data in children from one month of age with partial onset seizures. We conclude that the current data leading to the approval of levetiracetam for use in infants and children with partial onset seizures is encouraging, although more work needs to be done before definitive conclusions can be drawn about the efficacy of levetiracetam across different pediatric age groups.

show abstract

Controversies in the timing of pediatric epilepsy surgery: is earlier better?

Roland

2025

Pediatric Epilepsy Surgery Techniques

View full text Add to dashboard Cite

Rapid Dosage Titration of Levetiracetam in Children

Abstract: Rapid dosage titration of levetiracetam is feasible and well tolerated in children who require rapid escalation to therapeutic doses.

Cited by 4 publications

References 7 publications

The adverse event profile of levetiracetam: A meta-analysis on children and adults

The adverse event profile of levetiracetam: A meta-analysis on children and adults

Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age

Controversies in the timing of pediatric epilepsy surgery: is earlier better?

Contact Info

Product

Resources

About